Pay in 4 interest-free payments of $5.23 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Pentadecapeptide BPC 157 reduces bleeding time and thrombocytopenia after amputation [PMID: 21840572] Laboratory literature summary: Pentadecapeptide BPC 157 reduces bleeding time and thrombocytopenia after amputation in rats studied with heparin, warfarin or aspirin
Benzyl alcohol has been utilized in pharmaceutical and laboratory preparations for decades because of its antimicrobial properties
At 0.25mg weekly, one vial lasts 12 weeks
In the latter form, it is not produced for human ingestion or unsupervised self-administration
Mechanistically, BPC-157 does not operate through a single defined receptor
Patients who start with gut health optimization (peptide therapy as Phase 1) consistently respond better to subsequent therapies than patients who skip that step
